Aptar Pharma, the leading manufacturer of drug delivery systems for nasal applications worldwide, has now announced the installation of manufacturing capacity for its Child-Resistant and Senior-Friendly Classic Nasal Pump in their Congers, NY site.
A new assembly machine for the company’s Child-Resistant (CR) feature for nasal sprays was transferred from its plant in Southern Germany to Congers, NY. This represents an important step in bringing its manufacturing capacity closer to the target, said the company.
The Child-Resistant technology platform was developed primarily for the US market when, in 2012, the U.S. Consumer Product Safety Commission (CPSC) issued a rule requiring Child-Resistant packaging for any over-the-counter or drug product containing the equivalent of 0.08 milligrams or more of imidazoline (16 CFR Part 1700.14), a formulation widely used in nasal decongestant topical sprays.
Less than two years after the rule’s announcement, Aptar Pharma introduced its newly-engineered Child-Resistant/Senior-Friendly nasal spray pump to the U.S. market, which successfully matched the CPSC requirements. This feat once more underscored Aptar Pharma’s worldwide reputation as an innovative leader and trusted partner in the pharmaceutical industry.
The nasal sprays effectively combines Child-Resistance (CR) and Senior-Friendliness (SF) with its intuitive and widely-accepted squeeze-and-turn technology.
“We are pleased to welcome the arrival of Aptar Pharma’s Child-Resistant assembly machine to our recently-expanded Congers, NY manufacturing site. This added manufacturing capacity enables us to offer the production of this key Child-Resistant and Senior-Friendly feature to our customers domestically. This new initiative enables us to continue to support our important North American marketplace and increase our demand reactivity”, said Alex Theodorakis, President Aptar Pharma North America.